doi:10.1038/s41408-019-0176-xengRodríguez-Otero, P.Mateos, M.V.Martínez-López, J.Hernández, M.T.Ocio, E.M.Rosiñol, L.Martínez, R.Teruel, A.I.Gutiérrez, N.C.Bargay, J.Bengoechea, E.González, Y.de Oteyza, J.P.Gironella, M.Nuñez-Córdoba, J.M.Encinas, C.Martín, J.Cabrera, C.Palomera, L.de Arriba, F.Cedena, M.T.Puig, N.Oriol, A.Paiva, B.Bladé, J.Lahuerta, J.J.San Miguel, J.F.Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signatureART-2019-111193Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) = 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb = 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.2019http://zaguan.unizar.es/record/7883910.1038/s41408-019-0176-xhttp://zaguan.unizar.es/record/78839oai:zaguan.unizar.es:78839info:eu-repo/grantAgreement/EUR/ERC/MYELOMANEXU-2015info:eu-repo/grantAgreement/ES/ISCIII/CB16-12-00369info:eu-repo/grantAgreement/ES/ISCIII/CB16-12-00377info:eu-repo/grantAgreement/ES/ISCIII/CIBERONCinfo:eu-repo/grantAgreement/ES/ISCIII/FIS/CD13-00340info:eu-repo/grantAgreement/ES/ISCIII/FIS/G03-136info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI12-01761info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI12-02311info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI13-01469info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI14-01867info:eu-repo/grantAgreement/ES/ISCIII/FIS/PS09-01897-01370BLOOD CANCER JOURNAL 9, 4 (2019), 36byhttp://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccess